Recent Updates
Recently added Catalysts

Nitric Oxide

Phase 3

Bronchiolitis | Small molecule | Other |Beyond Air, Inc.|Last Updated: May 12, 2020

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials2
Total Enrollment112
FDA Designations
No designations recorded
Clinical trial landscape

Nitric Oxide · 5 trials · 4 indications

Phase 3 1Phase 2 2Phase 1 2
NCT03053388Evaluation of the Efficacy Safety and Tolerability of Nitric Oxide Given Intermittently Via Inhalation to Subjects With BronchiolitisBronchiolitis
COMPLETED69 Analytics
PHASE3COMPLETED
Evaluation of the Efficacy Safety and Tolerability of Nitric Oxide Given Intermittently Via Inhalation to Subjects With Bronchiolitis
BronchiolitisUnlock trial analytics
Study Endpoints
Primary Endpoints
Hospital Length of Stay (LOS)
12 days

LOS is measured in hours from the time of first treatment dose to the time of physician decision to discharge.

Time to "fit for discharge"
up to 14 days

Time to "fit for discharge". "Fit for discharge" is a composite endpoint measured by the following: * Achieving Modified Tal score \[mTal\] ≤ 5 And * Oxygen saturation (SpO2) ≥92% at room air (without oxygen supplementation) sustained for at least 2 hours Both of these will be determined from the time of enrollment (when the ICF is signed).

Safety measured by NO-related Serious Adverse Events
21 days
Met-Hemoglobin percentage (MetHb)associated with inhaled NO
1 month
Number of participants with adverse events associated with inhaled NO
1 month
Proportion of subjects (%) who prematurely discontinued the study for any reason
1 month
Proportion of subjects (%) who prematurely discontinued the study due to adverse events or serious adverse events
1 month
Met-Hemoglobin percentage (MetHb) associated with inhaled NO
21 days
Number of participants with adverse events associated with inhaled NO as a measure of safety and tolerability
5 days
Secondary Endpoints
Clinical score of ≤5 (Modified Tal score).
12 days
Oxygen saturation (SaO2) ≥92% in room air (without oxygen supplementation) sustained for at least 2 hours
12 days
Adverse events and NO-related adverse events including methemoglobinemia and nitrogen dioxide levels.
5 days
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Group 1 - Nitric Oxide treatmentEXPERIMENTAL• Group 1 (NO treatment) - will receive inhalations of 160 ppm NO combined with O2/air for 30 minutes, every 3-4.5 hours, five times a day (24 hours), for up to 5 days (maximum 25 inhalations), in addition to standard supportive treatment.
Group 2 - Control treatmentACTIVE_COMPARATOR• Group 2 (Control) - will receive inhalations O2/air using the same treatment schedule and equipment as group 1, in addition to standard supportive treatment.
Group 1- NO treatment- dose 1EXPERIMENTALWill comprise of approximately 30 patients and will receive inhalations of dose 1 of NO combined with O2/air for 40 minutes, every 4.5 hours during the day four times a day for up to 5 days in addition to standard supportive treatment.
Group 2- NO treatment- dose 2EXPERIMENTALWill comprise of approximately 30 patients and will receive inhalations of dose 2 of NO combined with O2/air for 40 minutes, every 4.5 hours during the day four times a day for up to 5 days in addition to standard supportive treatment.
Group 3- Control treatmentOTHERWill comprise of approximately 30 patients and will receive O2/air using the same treatment schedule and equipment as groups 1 and 2, in addition to standard supportive treatment.
Nitric Oxide treatmentEXPERIMENTAL -
Nitric oxide + standard treatmentEXPERIMENTALInhalation of 160 ppm NO for 30 minutes, 3 times daily, for a duration of 10 working days with the exclusion of weekend days (Friday \& Saturday) in which no treatment under this study will be provided.
Nitric oxide inhalation + standard treatmentEXPERIMENTALInhalation of 160 ppm gNO for 30 minutes, 5 times daily, for 5 consecutive days or until discharged, which occurs first.
Standard treatmentPLACEBO_COMPARATORStandard treatment
Interventions
NameTypeDescription
Nitric OxideDRUGNitric Oxide given via inhalation in cycles
Supportive treatmentOTHERSupportive treatment (including oxygen)
Standard Supportive treatmentOTHERStandard Supportive treatment (including oxygen)
PlaceboDRUG -
Unlock Study Design Details
Eligibility Criteria
Age RangeN/A to 12 Months
SexALL
Healthy VolunteersNo
Study Sites10

Inclusion Criteria: 1. 1\. Pediatric subjects 0-12-months old. a. Including subjects born at ≥28 weeks of gestation. 2. Subjects with acute bronchiolitis requiring in-patient hospitalization expected for 24 hours and more. 3. Clinical score of between 7 to 10 at Screening (without oxygen supple...

Countries:Israel
Unlock Eligibility Criteria